secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-049821
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09
----------------------------------------------------------------------

- Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.
- GAAP diluted EPS $1.09; non-GAAP diluted EPS $2.65, up from $0.48 a year ago.
- GAAP net income $124.8M vs loss $121.4M in Q3 2024; adjusted net income $303.7M.
- 47 abstracts accepted at ASH 2025; pipeline advances with sonrotoclax (BCL2 inhibitor) and BTK CDAC BGB-16673.
- Free cash flow $354.5M, up 548% from $54.7M in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/0001628280-25-049821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/bgne-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer